Under the leadership of Olivia Rossanese, we are seeking to appoint a Data Scientist to join the Centre for Target Validation at the ICR. The postholder will use machine learning and other AI bioinformatics approaches to identify/develop patient hypotheses, explore target/tumour links and discover biomarkers. Their work will contribute to target identification and validation activities within the centre, assist the clinical translation of our research and align with the ICR strategy to defeat cancer.
Key Requirements
The successful candidate must have proven experience in large scale cancer omics data analysis using machine learning (inlcuding feature extraction from large scale omics databases e.g. TCGA), R/Matlab statistical analysis skills, scripting skill (Perl/Python) and good working knowledge of Linux CLI. Network analysis experience and deep learning and other unsupervised AI approaches are highly desirable.
Department/Directorate Information:
The Division of Cancer Therapeutics, housing the Centre for Cancer Drug Discovery (CCDD), has an unrivalled track record at discovering novel cancer treatments for the personalised treatment of cancer. The Division also develops biomarkers designed to confirm the effectiveness of molecularly targeted therapies and help determine which therapy will benefit each patient.
The CCDD is a multidisciplinary 'bench to bedside' centre, comprising 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. We are one of the largest academic cancer drug discovery groups in the world and, with our collaborators, have discovered 21 preclinical development candidates, 12 of which have been progressed to clinical evaluation with our partners in the ICR/Royal Marsden Drug Development Unit. Our drug abiraterone (Zytiga) has been approved in the US, Canada and Europe for late-stage prostate cancer.
The CCDD’s mission is to develop personalised medicines by translating information from the cancer genome and cancer biology into drugs for patient benefit. We implement innovative drug discovery technologies, discover novel mechanism-based drugs, and develop these as rapidly as possible from the laboratory through to hypothesis-testing early clinical trials. All necessary science disciplines and technologies are in place to make this possible. Our biologists work alongside medicinal chemists focusing on new molecular targets emerging from human genome and cell biology research. In addition, we collaborate closely with colleagues throughout the ICR and beyond. Drug discovery is carried out in highly focused multi-disciplinary project teams analogous to those in a biotechnology company, with patient benefit as the primary driver. We also publish our work extensively and have a large network of collaborations with academia, biotechnology companies, and the pharmaceutical industry. The Division of Cancer Therapeutics is based in state-of-the art laboratories in the new £75m Centre for Cancer Drug Discovery building, opened in 2021 on the ICR Sutton campus.
We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Dr Konstantinos Mitsopoulos via Email on [email protected]